November 5, 2025
Recove Group Sdn Bhd
The NTIS team recently met with Recove Group Sdn. Bhd., the developer of REVA; A non-invasive device that measures haemoglobin levels without the need for blood extraction.
Approved under Sandbox 3 with a total funding of RM3.9 million, Recove Group is currently conducting its clinical trials at Hospital Canselor Tuanku Muhriz (HCTM) UKM and Klinik Kesihatan Bangi with 51.2% progress achieved to date.
The company aims to complete trials by Q1 2026, paving the way for the commercialisation of REVA a breakthrough solution that could enhance accessibility and comfort in healthcare diagnostics.
